Uplizna Market Report 2026

Uplizna Market Overview

• The Uplizna market growth in the historic period has been driven by improved diagnosis rates of multiple sclerosis, expansion of neurologist-led treatment protocols • Market expansion is supported by growing demand for convenient oral therapies, increasing focus on early intervention strategies • Growth Driver: Rising Prevalence Of Multiple Sclerosis Drives Growth Of The Market • Market Trend: Expanding Therapeutic Indications Through Positive Phase 3 Clinical Results • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Uplizna Market?

Uplizna (also known as ozanimod) is an oral medication approved for the treatment of relapsing forms of multiple sclerosis (MS). It functions as a sphingosine 1-phosphate receptor modulator, reducing the migration of immune cells to the central nervous system and helping manage MS symptoms. Uplizna (ozanimod) has been shown to reduce the frequency of relapses and slow the progression of disability in patients with relapsing MS, improving overall quality of life. The main indication for uplizna are neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG). Neuromyelitis optica spectrum disorder is a rare autoimmune condition affecting the central nervous system, leading to inflammation and damage in the optic nerves and spinal cord. These are ditributed through various distribution channel such as hospital and clinics, retail and specialty pharmacies. These are also used by various end users such as adult, and geriatric.

What Is The Uplizna Market Growth Forecast?

The growth in the forecast period can be attributed to growing demand for convenient oral therapies, increasing focus on early intervention strategies, expansion of personalized ms treatment plans, rising investments in neuroimmunology research, advancements in long-term efficacy studies. Major trends in the forecast period include increasing adoption of oral immunomodulatory therapies, growing demand for long-term ms management drugs, expansion of targeted immune modulation treatments, rising emphasis on patient adherence solutions, enhanced focus on relapse prevention.

Global Uplizna Market Segmentation

1) By Indication: Neuromyelitis Optica Spectrum Disorder (NMOSD), Generalized Myasthenia Gravis (gMG) 2) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 3) By End User: Adult, Geriatric

What Is The Driver Of The Uplizna Market?

The rising prevalence of multiple sclerosis is expected to propel the growth of the uplizna market going forward. Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to a range of neurological symptoms. The prevalence of multiple sclerosis (MS) can be attributed to factors such as improved diagnosis, increased awareness, an aging population, and genetic predisposition. Uplizna helps multiple sclerosis patients by targeting and depleting B cells to reduce inflammation and prevent disease progression, offering a promising solution for managing this chronic condition. For instance, in July 2024, according to the National Health Service (NHS) England, a UK-based government department, multiple sclerosis affects over 150,000 people in the UK, with more than 120,000 in England, and is more prevalent in women. Therefore, the rising prevalence of multiple sclerosis is driving the growth of the uplizna industry.

Key Players In The Global Uplizna Market

Major companies operating in the uplizna market are Amgen Inc.

Global Uplizna Market Trends and Insights

Major companies operating in this space are focusing on technological advancement in the form of late-stage clinical efficacy milestones and the associated regulatory-enabling activities, such as pivotal phase-3 trials and filings that can expand indications and support broader clinical adoption. Late-stage clinical milestones and regulatory enabling activities refer to the design, execution and successful readout of pivotal trials (demonstrating clinically meaningful efficacy and acceptable safety) together with subsequent regulatory engagement and filings the combination that converts investigational promise into label expansion, payer discussion and real-world use. For instance, in October 2024, Amgen Inc., a US-based biotechnology company, presented positive Phase 3 MINT trial results for UPLIZNA® (inebilizumab-cdon) in adults with generalized myasthenia gravis; the topline data showed clinically meaningful and statistically significant improvements on key endpoints and prompted plans for regulatory submission activities. These late-stage results strengthen the therapy’s evidence base, create a clear pathway toward a potential new indication, and can materially shift prescriber and payer perception by demonstrating durable symptom improvement with a manageable safety profile.

What Are Latest Mergers And Acquisitions In The Uplizna Market?

In June 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics Public Limited Company (PLC) for an undisclosed amount. With this acquisition, Amgen Inc. expanded its portfolio and capabilities in the biotechnology sector, potentially enhancing its research and development efforts and broadening its product offerings, thus enabling both companies to leverage their combined resources for innovation and growth in the healthcare industry. Horizon Therapeutics Public Limited Company (PLC) is an Ireland-based biopharmaceutical company specializing in developing uplizna.

Regional Insights

North America was the largest region in the uplizna market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Uplizna Market?

The uplizna market consists of sales of injectable solution (IV Infusion), pre-filled syringe, and vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Uplizna Market Report 2026?

The uplizna market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the uplizna industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.